The 2012 American Transplant Congress (ATC) held in Boston, USA from June 2–6 provided delegates with the opportunity to preview features of the LifePort Liver Transporter currently in development. In addition, visitors to the Organ Recovery Systems booth were given the chance to interact with the LifePort 1.1 Kidney Transporter and learn more about the company's UW solution – SPS-1 Static Preservation Solution.
Outside of the booth, Organ Recovery Systems were active in the educational field, proudly sponsoring an educational symposium titled: Improving post-transplantation outcomes: The mechanisms of machine perfusion.
Chairing the symposium was Dr Marlon Levy of Baylor All Saints Medical Center at Fort Worth, Texas, USA.
Dr Stefan G. Tullius, Chief of Transplant Surgery at Brigham and Women's Hospital and Associate Professor of Surgery at Harvard Medical School, Boston, USA presented on the potential mechanisms underlying pulsatile perfusion, reviewing the biological processes thought to be implicated in ischemia and reperfusion injury and providing an overview of how machine perfusion may have a positive effect in protecting against these insults.
Dr Michael Goldstein, from Mount Sinai Medical Center, New York, USA then presented data from over 1000 machine perfused SCD and ECD kidneys from the New York Organ Donor Network, looking at the potential use of machine measured renal resistance parameters as a diagnostic tool for predicting early graft function. In addition, Dr Goldstein provided an overview of the potential therapeutic effects of machine perfusion and discussed how pump time can be calculated to ameliorate the impact of DGF with prolonged models of cold ischemic time (CIT).
The final presentation was from Dr Michał Wszoła, of Warsaw Medical University, Poland, where they have a long history of machine perfusion with kidneys. Dr Wszoła reviewed the results of his group's 1-year prospective, comparative trial of machine perfusion in kidney transplantation, with one kidney pumped by the LifePort Kidney Transporter and the contralateral by the Waters machine.1 Dr Wszoła concluded that machine perfusion with the use of LifePort seems to be superior over machine perfusion with the Waters machine in preserving kidney function, particularly within those kidneys retrieved from the ECD population.
1. Wszoła M, et al. One-Year Transplantation Results of Kidneys Preserved by Machine Perfusion – LifePort Kidney Transporter Versus Waters RM3-Prospective Study. Abstract presented at the 2012 American Transplant Congress, June 2–6, 2012, Boston, USA.